Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

May 16, 2006 08:00 ET

Swiss Medica Launches PMS Escape Television Campaign

TORONTO, ONTARIO--(CCNMatthews - May 16, 2006) - Swiss Medica, Inc. (OTCBB:SWME) to announce that it is launching a television campaign for its PMS Escape product in the Midwest USA beginning this week. The 30-second television spot will air in Columbus, Ohio, Indianapolis, Indiana and Detroit Michigan from May 16 until June 10, 2006 and will highlight PMS Escape as a unique over-the-counter, patented, clinically tested and all-natural product for the mood and appetite symptoms of premenstrual syndrome.

Swiss Medica engaged Spot Runner, a new Internet-based advertising agency located in Los Angeles, Calif., to create the television spot and manage the campaign. Spot Runner specializes in making it fast, easy and affordable for businesses to advertise on TV. The PMS Escape 30 second TV may be viewed at

The commercial is intended to reach women between the ages of 25 and 45 suffering from the emotional and appetite problems of premenstrual syndrome. "We took a soft approach to reaching our target audience with our first-ever television spot," explains Wendy Kramer, Vice President of Swiss Medica. "We wanted to let women know that we understand how delicate this subject matter is and how important it is to see women like themselves who can conquer the age-old problems of PMS in a natural and healthy way," Kramer continues. "We look forward to great success with our new campaign."

The spot, which highlights how PMS Escape can help women get relief from the anger, irritability and tension of PMS, will be aired during The Today Show, Good Morning America, Ellen and Oprah in the Columbus market, while Indianapolis and Detroit will air the spot on stations such as HGTV, TNT and TBS. "By airing our spots during daytime television shows, we can reach women at a time when they will really listen to what we have to say about PMS Escape," Kramer continues.

PMS Escape is available in the Feminine Hygiene section of CVS/Pharmacy and Meijers and online at

About Swiss Medica, Inc.:

Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at, , and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information